The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation consortium analysis

JAMA

Volumn 276, Issue 19, 1996, Pages 1575-1579

  Eng, Charis ^a,c   Clayton, David ^d   Schuffenecker, Isabelle ^e   Lenoir, Gilbert ^e   Cote, Gilbert ^f   Gagel, Robert F ^f   Ploos Van Amstel, Hans Kristian ^g   Lips, Cornelis J M ^g   Nishisho, Isamu ^h   Takai, Shin Ichiro ^h   Marsh, Debbie J ^a,i   Robinson, Bruce G ⁱ   Frank Raue, Karin ^j   Raue, Friedhelm ^j   Xue, Feiyu ^k   Noll, Walter W ^k   Romei, Cristina ^l   Pacini, Furio ^l   Fink, Monika ^m   Niederle, Bruno ^m   Zedenius, Jan ⁿ   Nordenskjöld, Magnus ⁿ   Komminoth, Paul ^o   Hendy, Geoffrey N ^p   Gharib, Hossein ^q   Thibodeau, Stephen N ^q   Lacroix, André ^r   Frilling, Andrea ^s   Ponder, Bruce A J ^c,t   Mulligan, Lois M ^b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITY OF TEXAS   (United States)

^g UTRECHT UNIVERSITY   (Netherlands)

^h OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^l UNIVERSITY OF PISA   (Italy)

^m UNIVERSITY OF VIENNA   (Austria)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY OF ZURICH   (Switzerland)

^p ROYAL VICTORIA HOSPITAL   (Canada)

^q MAYO CLINIC   (United States)

^r CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^s UNIVERSITY OF HAMBURG   (Germany)

^t IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENE MUTATION; GENETIC LINKAGE; GENOTYPE; HUMAN; HYPERPARATHYROIDISM; MEDICAL DECISION MAKING; MULTIPLE ENDOCRINE NEOPLASIA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SCREENING; THYROID MEDULLARY CARCINOMA; TREATMENT PLANNING;

EID: 4644256817     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.19.1575     Document Type: Article

References (35)

1. Schimke RN. Genetic aspects of multiple endocrine neoplasia. Annu Rev Med. 1984;35:25-31.
2. Schimke RN, Hartmann WH, Prout TE, Rimoin DL. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med. 1968;279:1-7.
3. Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986;73:278-281.
4. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. Hirschsprung's disease in a family with multiple endocrine neoplasia. J Pediatr Gastroenterol Nutr. 1982;1:603-607.
5. Frilling A, Becker H, Roehr H-D. Unusual features of multiple endocrine neoplasia. Henry Ford Hosp Med J. 1992;40:233-235.
6. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989;111:802-806.
7. Mulligan LM, Kwok JBJ, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363:458-460.
8. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851-856.
9. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 1994;6:70-74.
10. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 1995;10:509-513.
11. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995;10:2415-2419.
12. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RE T proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
13. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET/proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994;3:237-241.
14. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994;91:1579-1583.
15. Reynolds LF, Eng C. RET mutations in the MEN 2 syndromes and Hirschsprung disease. Curr Opin Pediatr. 1995;7:702-709.
16. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2, related sporadic tumours and Hirschsprung disease. Hum Mutat. In press.
17. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 1996;81:2041-2046.
18. Pausova Z, Soliman E, Amizuka N, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. Baillieres J Clin Endocrinol Metab. 1996;81:2711-2718.
19. Attié T, Pelet A, Edery P, et al. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet. 1995; 4:1381-1386.
20. Angrist M, Bolk S, Thiel B, et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet. 1995;4:821-830.
21. Okamoto E, Ueda T. Embryogenesis of intramural ganglia of the gut and its relation to Hirschsprung disease. J Pediatr Surg. 1967;10:437-443.
22. Mulligan LM, Eng C, Attié T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994; 3:2163-2167.
23. Schuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet. 1994;3:1939-1943.
24. Thakker RV, Ponder BAJ. Multiple endocrine neoplasia.Clin Endocrinol Metab. 1988;28:1031-1068.
25. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in MEN 2: Report of the International RET Mutation Consortium. J Intern Med. 1995;238:343-346.
26. Lips CJM, Landsvater RM, Höppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828-835.
27. Marsh DJ, McDowall D, Hyland VJ, et al. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol. 1996;44:213-220.
28. Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1995; 80:3088-3090.
29. Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol. 1995; 43:123-127.
30. Ponder BAJ, Finer N, Coffey R, et al. Family screening in medullary thyroid carcinoma presenting without a family history. Q J Med. 1988;67:299-308.
31. Gardner E, Mulligan LM, Eng C, et al. Haplotype analysis of MEN 2 mutations. Hum Mol Genet. 1994;3:1771-1774.
32. Hofstra R, Stelwagen T, Stulp R, et al. RET mutations in MEN 2 associated diseases. Am J Hum Genet. 1994;55(suppl 3):A60.
33. Borst MJ, van Camp JM, Peacock ML, Decker RA. Mutation analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery. 1995;117:386-389.
34. Noorani HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet. 1996;59:301-307.
35. Komminoth P, Kunz EK, Matias-Guiu X, et al. Analysis of RET proto-oncogene point mutations distinguished heritable from nonheritable medullary thyroid carcinomas. Cancer. 1995;76:479-489.